Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apitegromab in Overweight and Obese Adult Subjects

Next Previous
Trial Profile

A Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apitegromab in Overweight and Obese Adult Subjects

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apitegromab (Primary) ; Semaglutide (Primary) ; Tirzepatide (Primary)
  • Indications Obesity
  • Focus Proof of concept; Therapeutic Use
  • Acronyms EMBRAZE
  • Sponsors Scholar Rock

Most Recent Events

  • 14 May 2025 According to Scholar Rock media release, topline data to be reported in June 2025.
  • 10 Sep 2024 Status changed to active, no longer recruiting, according to Scholar Rock media release.
  • 10 Sep 2024 According to Scholar Rock media release, trial completed enrollment in this Phase 2 EMBRAZE trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top